Stay updated with breaking news from Smart Factories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable
Bristol Myers Squibb (BMS) has entered into an agreement with Cellares to bolster the manufacturing of chimeric antigen receptor (CAR) T cell therapies.
Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale...
BUSINESS REPORT THIS IS AN ENGLISH TRANSLATION OF THE BUSINESS REPORT ORIGINALLY PREPARED IN THE KOREAN LANGUAGE . THIS ENGLISH TRANSLATION...